Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region

23 Nov 2022 10:05 CET

Oslo, 23 November 2022 - Navamedic has signed an agreement with its partner
InfoRLife SA (subsidiary of ACS Dobfar S.p.A.) which will expand Navamedic's
portfolio of antibiotics for hospital use. Under the agreement, Navamedic
acquires the rights and Marketing Authorizations for the unique Clindamycin
ready-to-administer bags developed and manufactured by InfoRLife AS. Navamedic
already markets Clindamycin in traditional ampoules as part of the large
portfolio of antibiotics acquired from ACS Dobfar in 2020. The innovative ready
-to-use product will thus complement this portfolio.

Clindamycin is a well-established antibiotic used in treatment of severe
infections, including staphylococcal bone and joint infections, chronic
sinusitis and infections of the lower respiratory tract. The primary benefits of
this ready-to-use packaging are a reduction in medication errors, the reduced
risk of contamination, storage at ambient temperature, as well as nurse time
saving and a reduction of waste.
"With our efficient market access and strong local competence we launch and
strive to enhance the value of products and brands, and this acquisition
demonstrates how we continue to build assets of owned products. Over the recent
months we have made a string of new product launches, partnerships and
acquisitions, all bringing us closer to our NOK 1 billion revenue target in the
mid- to long-term", says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

The Clindamycin ready-to-administer bags have been on the market in Norway,
Sweden and Denmark since 2020 under the label of Villerton (owned by ACS
Dobfar), mainly being sold through national and regional hospital tenders. The
transfer of the marketing authorizations will be initiated within short and the
product is expected to be on the market under the Navamedic label from early
2023.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62842

E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA:

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA).

More information:
Access the news on Oslo Bors NewsWeb site